Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951952 | 0.85 | HSD17B3 (0.48) | ESR1KDM4EMIFLMNA | |
| SCHEMBL19085086 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BCYP4F2CYP4A11RIPK1 | |
| SCHEMBL21554546 | 0.85 | CA2 (0.50) | CA2CAMK2AMTNR1AMTNR1BKDM4E | |
| SCHEMBL7517689 | 0.85 | HPGD (0.50) | MTNR1AMTNR1BCTBP2CYP4F2CYP4A11 | |
| SCHEMBL16447010 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BCYP4F2CYP4A11RIPK1 | |
| SCHEMBL5533824 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4ECTSSCTSK | |
| SCHEMBL21880654 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BCYP4F2CYP4A11RIPK1 | |
| SCHEMBL2427540 | 0.83 | MAPT (0.56) | MTNR1AMTNR1BLMNA | |
| SCHEMBL3135380 | 0.83 | KMT2A (0.53) | MTNR1AMTNR1BRIPK1RIPK3LMNA | |
| SCHEMBL5866843 | 0.83 | LOXL2 (0.46) | MTNR1AMTNR1BKDM4ECYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739663-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250214935-A1 | METHOD FOR PRODUCING ARYL ESTER-CONTAINING CARBOXYLIC ACID AND METHOD FOR PRODUCING CATIONIC LIPID | NOF CORPORATION (JP) | 2025-07-03 | — | — | US | disclosed |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025080850-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4506329-A1 | METHOD FOR PRODUCING ARYL ESTER-CONTAINING CARBOXYLIC ACID AND METHOD FOR PRODUCING CATIONIC LIPID | NOF Corporation (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025008510-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-118973994-A | Method for producing carboxylic acid containing aryl ester and method for producing cationic lipid | 日油株式会社 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024203577-A1 | CATIONIC LIPID HAVING DISULFIDE BOND | 国立大学法人東北大学 | 2024-10-03 | — | — | WO | disclosed |
| US-11839659-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | NORTHWESTERN UNIVERSITY (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023190164-A1 | METHOD FOR PRODUCING ARYL ESTER-CONTAINING CARBOXYLIC ACID AND METHOD FOR PRODUCING CATIONIC LIPID | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-101119756-A | Absorbent structure with improved water-absorbing material | PROCTER & GAMBLE (US) | 2008-02-06 | — | — | CN | disclosed |
| CN-1268618-C | 1,5-benzothiazepines compounds and its use as antilipemic agent | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | CN | disclosed |
| US-6974658-B2 | HIGH MOLECULAR COMPOUND, MONOMER COMPOUNDS AND PHOTOSENSITIVE COMPOSITION FOR PHOTORESIST, PATTERN FORMING METHOD UTILIZING PHOTOSENSITIVE COMPOSITION, AND METHOD OF MANUFACTURING ELECTRONIC COMPONENTS | KABUSHIKI KAISHA TOSHIBA (JP) | 2005-12-13 | — | — | US | disclosed |
| CN-1481373-A | 1,5-benzothiazepines compounds and its use as antilipemic agent | — | 2004-03-10 | — | — | CN | disclosed |
| US-6207343-B1 | RESIN CONTAINING GROUPS WHICH DECOMPOSE BY THE ACTION OF AN ACID TO ENHANCE ITS SOLUBILITY IN AN ALKALINE DEVELOPING SOLUTION AND A COMPOUND WHICH GENERATES AN ACID UPON IRRADIATION WITH ACTINIC RAYS OR RADIATION | FUJI PHOTO FILM CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-5229381-A | Inhibitors of leukocyte enzyme elastase | MERCK & CO., INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0481671-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0048954-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4348410-A | Cyclohexane carboxylic acid derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-09-07 | — | — | US | disclosed |
| EP-0048954-A2 | Beta-lactam compounds, process for the preparation thereof and intermediate products for the preparation thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839659-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | IDO1, IDO2, KMO | CA2 4388/4885CAMK2A 1365/4885SENP1 224/4885 |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | CA2 2432/4885CAMK2A 3463/4885SENP1 577/4885 |
| US-20250214935-A1 | METHOD FOR PRODUCING ARYL ESTER-CONTAINING CARBOXYLIC ACID AND METHOD FOR PRODUCING CATIONIC LIPID | LIPC, TSPO, CETP | CA2 3142/4885CAMK2A 3879/4885SENP1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.